Physioacoustic Ltd Finland

Mr Ilkka Turunen
LinkedIn logo CEO 

Project Tide / Tampere University of Technology Finland

Project Tide is commercializing novel respiration measurement technology developed at Tampere University of Technology. The first application of this technology platform is in DIAGNOSIS AND MANAGEMENT OF CHILDHOOD ASTHMA.

Because of the very limited methods for objective lung function measurement in young children their diagnostic procedures for asthma are currently based on qualitative and subjective estimates of the symptoms. Approximately 15 % of all children exhibit symptoms before school age. There have been technological attempts to solve this widely acknowledged problem, but none have been successful so far. Our approach is paradigm changing and will globally affect the course of pediatric asthma diagnosis and management.

Our innovative system enables lung function measurements with practically no need of co-operation from the child. The measurement is done over one 24h period and analysed for signs of asthma in the respiratory flow pattern.

The technology is currently in clinical trial phase with the leading pediatric asthma research group in Finland. The first phase results on asthmatic preschool children are very encouraging and will be published soon.

We are seeking seed funding to establish a company in Q2 / 2014.

Mr Ville-Pekka Seppä
Mr Ville-Pekka Seppä
LinkedIn logo Researcher / PhD student 

RemoteA / SuperECG Finland

SuperECG has developed the HeartBug, an affordable and reliable ECG device for the consumers.

With the help of the SuperECG HeartBug and an online analysis service anyone can conduct a cardiac assessment that used to always require a visit to a clinic. The heartBug records the heart’s electrical activity for up to 24 hours and the advanced cardiac analysis system produces a report. The extensive report points out possible findings indicating arrhythmia, as well as the effect of physical exercise on cardiac rhythm.

The technology applied in the device and the analysis software has previously been developed by the parent company RemoteA for several years.

Mr Tuomas Harju
LinkedIn logo International Sales Manager 

Smartvisio Ltd. Finland

Smartvisio care- and entertainment service runs on a cloud-based service platform which delivers communication and content services to the customers using standard audiovisual equipment – any standard TV and webcam are totally sufficient.   

Mr Jouni Mäkipää
Mr Jouni Mäkipää
LinkedIn logo CEO,  
Mr Tuomas Neuvonen
CEO 
Dr Jani Virtanen
COO, chairman 

TKS A/S Denmark

TKS Technology A/S (TKS), a Danish registered limited company, specialized in developing and marketing wireless interface systems which create a whole new meaning to digital control, mobility and communication. 

Having spent 10 years and approx. EUR 2.5 million on research, development and testing by selected users TKS is now ready to bring the Itongue® product to market.

Itongue® is an intra-oral device which makes the user able to control devices with the tongue. The tongue is controlled directly by the brain - not through the spinal cord. Therefore Itongue® can be used by people suffering from severe paralysis not able to use traditional controllers. Furthermore, Itongue® does not only have a number of advantages compared to other applications, it simply takes controlling to the next generation. It is the only CE - certified control of its kind.

The intra-oral device is wirelessly connected to an external control unit which can be connected to control everything from computer keyboard and mouse to an electric wheelchair.

Based on the Itongue® platform TKS currently has planned 2 more innovative products in the pipeline. The first generation of Itongue® - now ready to be marketed - requires the user to get a tongue-piercing. The second generation – presently being developed - will not require a tongue piercing and will therefore be able to address a broader market such as surgeons, military jet pilots, gamers etc. Based on the current version of Itongue®. TKS is also developing a finger controlled version which is aimed at bringing better control capabilities to disabled who still have some movement capabilities in their fingers.

Having obtained a CE approval the Itongue® is now ready to be marketed as medical device in the EU.

Total global market which can be addressed by the Itongue® product is estimated to more than EUR 200 million annually with a split of approx. 40 per cent in Europe and 30 per cent in the US and with an expected growth rate of more than 100% per cent p.a.

Management of TKS expects to obtain some sales in 2013 and meet revenue objectives for 2014 of EUR 4 million, and in 2015 of EUR 10 million. Markets will be addressed through a combination of own sales force and external partners. Costumers for the first version of Itongue® are to be found among manufacturers of different types of medical devices e.g. wheelchairs.

The Company has now entered into a phase where the present owners and management are seeking a new owner / out-side co-investor who could add the required expertise and knowledge to commercialize the Company and its products - in other words to bring TKS and its products efficiently to the market; not only domestically but also in a number of international markets. An investment amount in the region of EUR 2 million is targeted in order to be able to full fill the business plan set up by the management of TKS. 

Basis organisation

Gert Spender, Exec. MBA, CEO 

Søren Mørch, M.Sc, development engineer (electronics) 

Jan Maltha, M.Sc. IT, development engineer (software) 

Poul Hansen, M.Sc. IT, development engineer (software) 

Hugo Bertelsen & Kirsten Berthelsen, interim technical project manager

Clinical trials partners and consultants

Lotte N.S. Andreasen Struijk, PhD (scientist and inventor), principal investigator 

Bo Bentsen (dentist) system encapsulation and materials

Dirk Leonhart (dental chief technician), Aarhus Dental College

Michael Gaihede, principal clinical investigator, Aalborg Hospital

Morten Haugland (reviewer), founder of Neurodan, currently scientific specialist of Medotech 

MediQA Consulting, Internal quality assurance and regulatory

DMD-Consulting, Poul Schmidt-Andersen, Managing Partner, B.Sc.E.E, B.Comm,

Compliance with EU and US regulatory requirements

Associated researchers

Lotte N.S. Andreasen Struijk, PhD, Associated Professor AAU

Fin Bering Sørensen, Professor dr. Med.

Eugen R. Lontis, PhD, development engineer (sensor technology design)

Hector A. Caltenco, PhD student (smart dictionary for the key pad)

Daniel Johansen, PhD student (SmartHand, control of hand prosthesis)

Brugerpanel (usergroup)


Mr Gert Spender
Mr Gert Spender
LinkedIn logo CEO 
Mr Heikki Kallasvaara
Manager, Foresight and Networks